GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2018-2026

  • You are here:
  • Home
  • Reports
  • GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2018-2026

GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2018-2026

The Global Alzheimer’s disease diagnostic and therapeutic market is anticipated to grow at a CAGR of 7.50% between 2018 and 2026. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that mostly affects people above the age of 65. The Alzheimer’s disease diagnostic and therapeutic market is primarily driven by the following factors:

GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2018-2026

Global Alzheimer’s Disease Therapeutics and Diagnostics Market by Therapeutics and Diagnostic (Drugs,  Disease Stage, Generic and Branded, Diagnostics) by Geography

Request free sample

The Global Alzheimer’s disease diagnostic and therapeutic market is anticipated to grow at a CAGR of 7.50% between 2018 and 2026. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that mostly affects people above the age of 65. The Alzheimer’s disease diagnostic and therapeutic market is primarily driven by the following factors:

  • Growing geriatric population
  • The rise in the pervasiveness of Alzheimer’s disease
  • Increasing healthcare expenditure
  • Government investment in research and development

Alzheimer’s Disease Diagnostics and Therapeutics Market

To learn more about this report, request a free sample copy

The important driver increasing growth in the global Alzheimer’s disease diagnostic and therapeutic market is the rise in the pervasiveness of Alzheimer’s disease. The high prevalence of Alzheimer’s disease globally acts as a key driver for the growth of the global Alzheimer’s disease therapeutics and diagnostics market and emphasizes the need to develop an effective Alzheimer’s disease treatment. For instance, according to the Alzheimer’s Association in 2016, a projected 5.4 million of the American residents across every age group suffer from Alzheimer’s.

The Therapeutics and diagnostics of Alzheimer’s disease diagnostic and therapeutic market are used extensively for the treatment of Alzheimer’s diseases. The Alzheimer’s disease therapeutics and diagnostics market is segmented into therapeutics and diagnostics. Global Alzheimer’s disease therapeutics and diagnostics by marketed drugs market comprise of the market for drugs such as NMDA receptor antagonists, Cholinesterase inhibitors and other drugs that are used for therapeutic treatment of Alzheimer’s. The general course of the AD is categorized into seven stages according to disease severity; however, because it is difficult to clearly distinguish each stage, in drug development a three-stage categorization is preferred: mild, moderate and severe AD. Treatment, or more accurately the prevention of AD, during the prodromal stage of the disease, is an expected trend for the global market for AD therapeutics in the mid-term future. A branded medicine is the original product that has been developed by a pharmaceutical company. Generic drugs are replicas of brand-name medicines that have precisely the effects and side effects, intended use, same dosage, route of administration, safety, risks, and forte as the novel drug. Alzheimer’s disease therapeutics and diagnostic market by diagnostics include the market for diagnostics biomarker.

Stringent government regulations and the high cost of therapies used for the treatment of Alzheimer’s Disease are the major factors hindering the Alzheimer’s disease diagnostic and therapeutic market. As per the Alzheimer’s Drug Discovery Foundation, pharmacologic treatments for Alzheimer are first tested in clinical trials registered with ‘Clinical Trials Government’, a national institute of health registry of publicly and privately funded clinical studies. The high cost of therapies used for the treatment of Alzheimer’s disease is one of the major factors restraining the growth of global Alzheimer’s disease therapeutics and diagnostics market.

The Global Alzheimer’s disease diagnostic and therapeutic market segment includes therapeutics and diagnostics.

Therapeutics and diagnostics are further segmented into:

  • Therapeutics
    • Therapeutics by drugs
      • Marketed drugs
      • Pipeline drugs
    • Therapeutics by disease stage
      • Late stage: severe ad
      • Early/middle stage: mild to moderate ad
      • Prodromal stage
    • Therapeutics by generic and branded
      • Branded
      • Generic
    • Diagnostics
      • Lumbar puncture test
      • Positron emission tomography
      • Electroencephalography
      • Magnetic resonance imaging
      • Computed tomography
      • Other diagnostics

This report covers the present market conditions and the growth prospects of the global Alzheimer’s disease diagnostic and therapeutic market for 2018-2026 and considered the revenue generated through the sales of Alzheimer’s disease diagnostic and therapeutics to calculate the market size by considering 2017 as the base year.

Geographically, the global Alzheimer’s disease diagnostic and therapeutic market has been segmented on the basis of four major regions, which include:

The Alzheimer’s disease diagnostic and therapeutic market in North America is expected to hold the largest share by 2026 owing to the rising prevalence of Alzheimer’s disease along with investments made by the government institutions in research & development activities for Alzheimer’s. Due to the prospect of new therapies gaining market approval and the anticipated growth in sales of the extended-release formulation of Namenda and  Namenda XR, the market for AD therapeutics in North America is anticipated to increase. On the other hand, the Asia-Pacific market is anticipated to be the fastest-growing region for the Alzheimer’s disease diagnostic and therapeutic market. Aggressive marketing and sales of AD therapeutics in India and China, and the introduction of the three globally common AD therapeutics, Exelon (rivastigmine), Reminyl (galantamine) and Memary (memantine) in Japan is likely to fuel the growth in the market for AD therapeutics in Asia-Pacific through the projected years.

The major market players in the global Alzheimer’s disease diagnostic and therapeutic market are:

  • ABBVIE INC.
  • AXON NEUROSCIENCE SE
  • BIOGEN INC.
  • HOFFMANN-LA ROCHE AG
  • MERCK AND CO.

Company Profiles covers analysis of important players.

AbbVie is a global, research-based biopharmaceutical company that was spun off from Abbott Laboratories in 2011 to intensify research-based pharmaceutical development. AbbVie develops and markets advanced therapies that are used for treating chronic autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease; low testosterone; HIV; endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease (CKD) and cystic fibrosis, among other health conditions. Merck and Co. is the world’s seventh largest pharmaceutical company by market capitalization and revenue. Its headquarters is located in New Jersey, the U.S. The company is currently carrying out Phase II and III clinical studies on the treatment of Alzheimer’s disease.

Key Findings of the Global Alzheimer’s disease diagnostic and therapeutic market:

  • Computed tomography is majorly used in the diagnostics of Alzheimer’s disease
  • Therapeutics market constitutes the largest market share
  • North America is the market leader in Alzheimer’s disease diagnostic and therapeutic market
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • COMPUTED TOMOGRAPHY IS MAJORLY USED IN THE DIAGNOSTICS OF ALZHEIMER’S DISEASE
      • THERAPEUTICS MARKET CONSTITUTES THE LARGEST MARKET SHARE
      • NORTH AMERICA IS A MARKET LEADER FOR ALZHEIMER’S DISEASE DIAGNOSTIC AND THERAPEUTIC MARKET
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • GROWING GERIATRIC POPULATION
      • RISE IN THE PERVASIVENESS OF ALZHEIMER’S DISEASE
      • INCREASING HEALTHCARE EXPENDITURE
      • GOVERNMENT INVESTMENT IN RESEARCH AND DEVELOPMENT
    • MARKET RESTRAINTS
      • STRINGENT GOVERNMENT REGULATIONS
      • HIGH COST OF THERAPIES USED FOR THE TREATMENT OF ALZHEIMER’S DISEASE
    • MARKET OPPORTUNITIES
      • ADVANCEMENTS IN IN-VITRO DIAGNOSTIC TECHNIQUES
      • INCREASING R&D INVESTMENT IN PERSONALIZED MEDICINES
    • MARKET CHALLENGES
      • LACK OF SKILLED MEDICINAL PRACTITIONERS FOT THE TREATMENT OF ALZHEIMER’S DISEASE
      • DEARTH OF AWARENESS CONCERNING NEW THERAPIES IN THE ALZHEIMER’S DISEASE
  1. MARKET SEGMENTATION
    • MARKET BY THERAPEUTICS AND DIAGNOSTIC 2018-2026
      • THERAPEUTICS
        • THERAPEUTICS BY DRUGS
          • MARKETED DRUGS
          • PIPELINE DRUGS
        • THERAPEUTICS BY DISEASE STAGE
          • LATE STAGE: SEVERE AD
          • EARLY/MIDDLE STAGE: MILD TO MODERATE AD
          • PRODROMAL STAGE
        • THERAPEUTICS BY GENERIC AND BRANDED
          • BRANDED
          • GENERIC
        • DIAGNOSTICS
          • LUMBAR PUNCTURE TEST
          • POSITRON EMISSION TOMOGRAPHY
          • ELECTROENCEPHALOGRAPHY
          • MAGNETIC RESONANCE IMAGING
          • COMPUTED TOMOGRAPHY
          • OTHER DIAGNOSTICS
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCE MODEL
      • THREAT OF NEW ENTRANTS
      • THREATS OF SUBSTITUTE PRODUCT
      • BARGAINING POWER OF BUYER
      • BARGAINING POWER OF SUPPLIER
      • INTENSITY OF COMPETITIVE RIVALRY
    • KEY BUYING CRITERIA
      • PRICE
      • EFFICIENCY
      • SAFETY
    • ETYMOLOGY OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
    • PARENT MARKET ANALYSIS
    • INVESTMENTS ANALYSIS
      • RESEARCH AND DEVELOPMENT
      • RAW MATERIALS
      • MANUFACTURING
      • WHOLESALERS
      • END USER
    • REGULATORY FRAMEWORK
    • THE UNITED STATES AND EUROPE REGULATORY AGENCY
    • ALZHEIMER’S DISEASE ETIOLOGY
    • PHASES AND STERNNESS OF ALZHEIMER’S DISEASE
    • PIPELINE ANALYSIS
    • COMPANION DIAGNOSTICS
  2. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • AUSTRALIA
      • REST OF ASIA PACIFIC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
  1. COMPANY PROFILES
    • COMPETITIVE LANDSCAPE
      • MARKET SHARE ANALYSIS
    • ABBVIE INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • AMARANTUS BIOSCIENCE HOLDINGS, INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • AXON NEUROSCIENCE SE
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVE
    • BAXTER INTERNATIONAL INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
    • BIOGEN INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • COGNOPTIX INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • DIAGENIC ASA
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
    • HOFFMANN-LA ROCHE AG
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • GE HEALTHCARE
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • MERCK AND CO.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • PFIZER INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC ANALYSIS
    • PIRAMAL ENTERPRISES LTD.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SIEMENS MEDICAL SOLUTIONS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SUN PHARMA
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SCOT ANALYSIS
      • STRATEGIC INITIATIVES

 

TABLE LIST

TABLE  1      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  2      PHARMACOLOGICAL TREATMENT OF BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD) OF ALZHEIMER’S

TABLE  3      DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER’S DISEASE

TABLE  4      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2018-2026 ($ MILLION)

TABLE  5      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2018-2026 ($ MILLION)

TABLE  6      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  7      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  8      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2018-2026 ($ MILLION)

TABLE  9      GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  10    GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  11    GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  12    GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED 2018-2026 ($ MILLION)

TABLE  13    GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN BRANDED BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  14    GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN GENERIC BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  15    GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY TYPES 2018-2026 ($ MILLION)

TABLE  16    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  17    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  18    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  19    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  20    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  21    GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS BY GEOGRAPHY 2018-2026 ($ MILLION)

TABLE  22    GLOBAL ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET BY GEOGRAPHY 2018-2026

TABLE  23    NORTH AMERICA ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

TABLE  24    EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

TABLE  25    ASIA PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

TABLE  26    ASIA PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

TABLE  27    REST OF WORLD ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE LIST          

FIGURE  1    GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2018-2026 ($ MILLION)

FIGURE  2    PEOPLE SUFFERING FROM ALZHEIMER’S DEMENTIA IN THE UNITED STATES  OF DIFFERENT AGES 2017 (%)

FIGURE  3    RISING HEALTH EXPENDITURE IN THE UNITED STATES ($ PER CAPITA)

FIGURE  4    COSTS OF CARE FOR PEOPLE WITH ALZHEIMER’S AND OTHER DEMENTIAS 2017 ($ BILLION)

FIGURE  5    GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2018-2026 ($ MILLION)

FIGURE  6    GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS2018-2026 ($ MILLION)

FIGURE  7    INVESTMENTS IN ALZHEIMER’S DISEASE TREATMENT

FIGURE  8    ALZHEIMER’S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE  9    GLOBAL CLINICAL TRIALS ON ALZHEIMER’S DRUG BY MECHANISM OF ACTION (%)

FIGURE  10  FDA-APPROVED CDX-DRUG PAIRS BY MOLECULAR TARGET

FIGURE  11  THE UNITED STATES ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  12  CANADA ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  13  EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  14  THE UNITED KINGDOM ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  15  FRANCE ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  16  GERMANY ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  17  SPAIN ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  18  REST OF EUROPE ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  19  CHINA ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  20  INDIA ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  21  JAPAN ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  22  AUSTRALIA ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  23  REST OF ASIA PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  24  REST OF WORLD ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  25  LATIN AMERICA ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  26  MIDDLE EAST & AFRICA ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2018-2026

FIGURE  27  MARKET SHARE ANALYSIS OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2017 (%)

  1. MARKET SEGMENTATION
    • MARKET BY THERAPEUTICS AND DIAGNOSTIC 2018-2026
      • THERAPEUTICS
        • THERAPEUTICS BY DRUGS
          • MARKETED DRUGS
          • PIPELINE DRUGS
        • THERAPEUTICS BY DISEASE STAGE
          • LATE STAGE: SEVERE AD
          • EARLY/MIDDLE STAGE: MILD TO MODERATE AD
          • PRODROMAL STAGE
        • THERAPEUTICS BY GENERIC AND BRANDED
          • BRANDED
          • GENERIC
        • DIAGNOSTICS
          • LUMBAR PUNCTURE TEST
          • POSITRON EMISSION TOMOGRAPHY
          • ELECTROENCEPHALOGRAPHY
          • MAGNETIC RESONANCE IMAGING
          • COMPUTED TOMOGRAPHY
          • OTHER DIAGNOSTICS
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • THE UNITED KINGDOM
      • FRANCE
      • GERMANY
      • SPAIN
      • REST OF EUROPE
    • ASIA PACIFIC
      • CHINA
      • INDIA
      • JAPAN
      • AUSTRALIA
      • REST OF ASIA PACIFIC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now